China SXT Pharmaceuticals, Inc. (SXTC)

China SXT Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	1.54	1.74	1.93	1.97	2.6	4.78
Revenue Growth (YoY)	-15.42%	-9.73%	-2.19%	-24.23%	-45.53%	-7.45%
Cost of Revenue	1.2	1.37	1.37	1.55	1.35	1.94
Gross Profit	0.33	0.37	0.55	0.43	1.25	2.84
Selling, General & Admin	8.72	3.05	2.65	5.68	6.44	5.04
Operating Expenses	8.72	3.05	2.65	5.68	6.44	5.04
Operating Income	-8.38	-2.68	-2.09	-5.26	-5.19	-2.2
Interest Expense	-0.68	-0.84	-0.55	-0.48	-0.04	-1.12
Interest & Investment Income	0.19	0.19	0.01	-	0	0.01
Other Non Operating Income (Expenses)	0.01	0.03	-0.04	0.15	-0.18	0.36
EBT Excluding Unusual Items	-8.87	-3.3	-2.68	-5.59	-5.41	-2.94
Asset Writedown	-	-	-0.42	-0.35	-	-
Pretax Income	-8.87	-3.3	-3.1	-5.93	-5.41	-2.94
Income Tax Expense	-	-	-	-	0.33	-0.19
Net Income	-8.87	-3.3	-3.1	-5.93	-5.74	-2.75
Net Income to Common	-8.87	-3.3	-3.1	-5.93	-5.74	-2.75
Free Cash Flow	-2.74	-2.35	-1.94	-0.15	0.21	-1.41
Gross Margin	21.74%	21.11%	28.73%	21.62%	48.10%	59.44%
Operating Margin	-544.94%	-153.97%	-108.49%	-266.68%	-199.43%	-45.99%
Profit Margin	-576.72%	-189.77%	-160.67%	-301.00%	-220.43%	-57.52%
Free Cash Flow Margin	-178.33%	-134.83%	-100.34%	-7.68%	7.91%	-29.50%
EBITDA	-8.34	-2.6	-1.89	-5.01	-4.87	-1.85
EBITDA Margin	-	-149.24%	-97.95%	-253.99%	-187.13%	-38.76%
D&A For EBITDA	0.05	0.08	0.2	0.25	0.32	0.35
EBIT	-8.38	-2.68	-2.09	-5.26	-5.19	-2.2
EBIT Margin	-	-153.97%	-108.49%	-266.68%	-199.43%	-45.99%
Revenue as Reported	1.54	1.74	1.93	1.97	2.6	4.78

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q